These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3016233)

  • 1. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
    Worland PJ; Jarrott B
    J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril.
    Ajayi AA; Campbell BC; Kelman AW; Howie C; Meredith PA; Reid JL
    Int J Clin Pharmacol Res; 1985; 5(6):419-27. PubMed ID: 3005181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
    Lin JH; Chen IW; Ulm EH; Duggan DE
    Drug Metab Dispos; 1988; 16(3):392-6. PubMed ID: 2900730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.
    Kelly JG; Doyle GD; Carmody M; Glover DR; Cooper WD
    Br J Clin Pharmacol; 1988 Dec; 26(6):781-6. PubMed ID: 2853960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline.
    Bull HG; Thornberry NA; Cordes MH; Patchett AA; Cordes EH
    J Biol Chem; 1985 Mar; 260(5):2952-62. PubMed ID: 2982845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional haemodynamic effects of captopril, enalaprilat and lisinopril in conscious water-replete and water-deprived Brattleboro rats.
    Muller AF; Gardiner SM; Compton AM; Bennett T
    Clin Sci (Lond); 1990 Oct; 79(4):393-401. PubMed ID: 2171862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-resolved fluoroimmunoassay for the determination of lisinopril and enalaprilat in human serum.
    Yuan AS; Gilbert JD
    J Pharm Biomed Anal; 1996 May; 14(7):773-81. PubMed ID: 8809701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.
    Semple PF; Cumming AM; Meredith PA; Morton JJ
    Cardiovasc Drugs Ther; 1987; 1(1):45-50. PubMed ID: 2856460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans.
    Kawamura M; Imanishi M; Matsushima Y; Akabane S; Kuramochi M; Ito K; Omae T
    Jpn J Pharmacol; 1990 Oct; 54(2):143-9. PubMed ID: 1963909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of renal function on enalapril kinetics.
    Lowenthal DT; Irvin JD; Merrill D; Saris S; Ulm E; Goldstein S; Hichens M; Klein L; Till A; Harris K
    Clin Pharmacol Ther; 1985 Dec; 38(6):661-6. PubMed ID: 2998676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol.
    Bendtsen F; Henriksen JH
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():139-45. PubMed ID: 2550636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Hockings N; Ajayi AA; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):341-8. PubMed ID: 3011046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitory effect of N-alpha-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (MK-0521) on angiotensin converting enzyme in vitro].
    Ino Y; Oda M; Sato T; Iwaki M
    Nihon Yakurigaku Zasshi; 1989 Apr; 93(4):219-24. PubMed ID: 2545578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril.
    Swaan PW; Stehouwer MC; Tukker JJ
    Biochim Biophys Acta; 1995 May; 1236(1):31-8. PubMed ID: 7794953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Mojaverian P; Rocci ML; Vlasses PH; Hoholick C; Clementi RA; Ferguson RK
    J Pharm Sci; 1986 Apr; 75(4):395-7. PubMed ID: 3014110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
    Bünning P
    Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
    Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B
    Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme inhibition in plasma and tissues.
    Johnston CI; Cubela R; Sakaguchi K; Jackson B
    Clin Exp Hypertens A; 1987; 9(2-3):307-21. PubMed ID: 3038391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.